ATE555383T1 - Lösliche heterodimere rezeptoren und ihre verwendung - Google Patents

Lösliche heterodimere rezeptoren und ihre verwendung

Info

Publication number
ATE555383T1
ATE555383T1 AT07786810T AT07786810T ATE555383T1 AT E555383 T1 ATE555383 T1 AT E555383T1 AT 07786810 T AT07786810 T AT 07786810T AT 07786810 T AT07786810 T AT 07786810T AT E555383 T1 ATE555383 T1 AT E555383T1
Authority
AT
Austria
Prior art keywords
constructs
linked
domain
soluble
immunoglobulin
Prior art date
Application number
AT07786810T
Other languages
German (de)
English (en)
Inventor
Petrus Spee
Soren Padkfr
Birgitte Friedrichsen
Inga Nyrby
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE555383T1 publication Critical patent/ATE555383T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT07786810T 2006-06-22 2007-06-22 Lösliche heterodimere rezeptoren und ihre verwendung ATE555383T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06115901 2006-06-22
PCT/EP2007/056276 WO2007147898A1 (en) 2006-06-22 2007-06-22 Soluble heterodimeric receptors and uses thereof

Publications (1)

Publication Number Publication Date
ATE555383T1 true ATE555383T1 (de) 2012-05-15

Family

ID=36764002

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07786810T ATE555383T1 (de) 2006-06-22 2007-06-22 Lösliche heterodimere rezeptoren und ihre verwendung

Country Status (6)

Country Link
US (1) US7932055B2 (https=)
EP (1) EP2035452B1 (https=)
JP (1) JP5368301B2 (https=)
AT (1) ATE555383T1 (https=)
ES (1) ES2385754T3 (https=)
WO (1) WO2007147898A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
US10329348B2 (en) 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
EP3373970A4 (en) 2015-11-13 2019-07-10 Dana Farber Cancer Institute, Inc. NKG2D IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY
WO2017156461A2 (en) * 2016-03-10 2017-09-14 Aperisys, Inc. Antigen-binding fusion proteins with modified hsp70 domains
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
CN108101975B (zh) * 2017-12-14 2020-05-15 中国科学院昆明动物研究所 一种森林山蛭抗血栓多肽Sylvestin及其体外表达制备方法和应用
EP3749685A4 (en) * 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
WO2019175182A1 (en) 2018-03-13 2019-09-19 Innate Pharma Treatment of head and neck cancer
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
MX2021006194A (es) * 2018-12-02 2021-06-30 Fate Therapeutics Inc Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
JP2022532430A (ja) * 2019-05-16 2022-07-14 シャタック ラボ，インコーポレイテッド Ｎｋ細胞指向性キメラタンパク質
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
EP3999850A1 (en) * 2019-07-16 2022-05-25 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Nmda receptor constructs to detect and isolate nmdar autoantibodies
CN111303296B (zh) * 2019-12-16 2021-01-29 启辰生生物科技(珠海)有限公司 双功能融合多肽、细胞和药物组合物及应用
CN111122848A (zh) * 2019-12-30 2020-05-08 浙江工业大学 一种用于筛选hgfr靶向抗体的elisa试剂盒及应用
EP4615978A1 (en) * 2022-11-07 2025-09-17 Senti Biosciences, Inc. Methods and compositions for cell-surface co-localization of chimeric proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
JPH06506358A (ja) 1991-03-28 1994-07-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ ナチュラルキラー細胞に特異的なｄｎａおよびアミノ酸配列
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
ITFI940106A1 (it) 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
CA2258721C (en) 1996-07-12 2014-09-09 Genentech, Inc. Chimeric heteromultimer adhesins
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6982142B2 (en) 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
EP1047781B1 (en) 1998-01-23 2004-07-28 Immunex Corporation Il-18 receptors
EP1001030A1 (en) * 1998-09-22 2000-05-17 Boehringer Ingelheim International GmbH Recombinant CELO virus and CELO virus DNA
HUP0204475A2 (en) * 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6853997B2 (en) 2000-06-29 2005-02-08 Infoglide Corporation System and method for sharing, mapping, transforming data between relational and hierarchical databases
IL137419A0 (en) 2000-07-20 2001-07-24 Yissum Res Dev Co Nk cells activating receptors and their therapeutic and diagnostic uses
US20020052475A1 (en) * 2000-07-20 2002-05-02 Schering Ag High affinity soluble interleukin-18 receptor
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
ATE333888T1 (de) 2000-09-15 2006-08-15 Zymogenetics Inc Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
CN1533438A (zh) 2001-06-08 2004-09-29 �����Ŵ��Ƽ���˾ 在植物生产蛋白质的方法
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers

Also Published As

Publication number Publication date
EP2035452A1 (en) 2009-03-18
JP2009541274A (ja) 2009-11-26
US7932055B2 (en) 2011-04-26
JP5368301B2 (ja) 2013-12-18
ES2385754T3 (es) 2012-07-31
WO2007147898A1 (en) 2007-12-27
EP2035452B1 (en) 2012-04-25
US20090281035A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
ATE555383T1 (de) Lösliche heterodimere rezeptoren und ihre verwendung
JP2015502373A5 (https=)
EA201290568A1 (ru) Связывающие гетеродимер протеины и их применение
FI3596125T3 (fi) Anti-PAR2-vasta-aineita ja niiden käyttöjä
RU2014109557A (ru) Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
AR077088A1 (es) Proteinas biespecificas de union a antigeno
CO6160305A2 (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
PE20240096A1 (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
AR078111A1 (es) Anticuerpos del antigeno carcinoembrionario (cea)
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
PE20091571A1 (es) Anticuerpos dirigidos a angiopoyetina-1 y angiopoyetina-2
AR052285A1 (es) Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
EA201001678A1 (ru) Способы идентификации противовоспалительных соединений
RU2015100230A (ru) Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
EP3670534A3 (en) Human fgf receptor and beta-klotho binding proteins
PE20060376A1 (es) ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
AR084141A1 (es) Anticuerpos neutralizadores anti-ccl20
ATE510561T1 (de) Kdr-spezifische menschliche antikörper und ihre verwendung